ANURAS.NS Stock Analysis
AN
Avoid
Based on Eyestock quantitative analysis, ANURAS.NS`s fundamental data and valuation indicate an investment grade of Avoid at the current time.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Upside
To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.
Overvalued
Market cap $B
0.626
Dividend yield
0.28 %
Shares outstanding
109.79 B
Anupam Rasayan India Ltd. manufactures pharmaceutical and specialty chemical products. The company is headquartered in Surat, Gujarat and currently employs 1,532 full-time employees. The company went IPO on 2021-03-24. The Company’s segments include Life Science Related Specialty Chemicals and Other Specialty Chemicals. The company manufactures a variety of life science related specialty chemicals comprising products related to agrochemicals, personal care, and pharmaceuticals. The firm manufactures agro intermediates and agro active ingredients for the agrochemicals industry, which are used in the manufacture of, amongst others, insecticides, fungicides, and herbicides. For the personal care industry, it provides, amongst others, anti-bacterial and ultraviolet protection intermediates, and ingredients. In the pharmaceutical segment, the Company focuses on developing intermediates and key starting materials for active pharmaceutical ingredients. The Company’s other specialty chemicals are used in diverse end-user segments, comprising specialty pigments, specialty dyes and polymer additives.